Aimée R. Kreimer

Aimée R. Kreimer Aimée Rebecca Kreimer (born August 19, 1975) is an American cancer epidemiologist who researches the etiology and prevention of human papillomavirus infection (HPV) and cancer prevention. She is a senior investigator in the infections and immunoepidemiology branch at the National Cancer Institute. Provided by Wikipedia
Showing 1 - 8 results of 8 for search 'Aimée R. Kreimer', query time: 0.04s Refine Results
  1. 1
    Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies.

    Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. by Ruth M Pfeiffer, Yikyung Park, Aimée R Kreimer, James V Lacey, David Pee, Robert T Greenlee, Saundra S Buys, Albert Hollenbeck, Bernard Rosner, Mitchell H Gail, Patricia Hartge

    Published 2013-01-01
    Get full text
    Article
  2. 2
    HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

    HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection by Daniel C. Beachler, Tim Waterboer, Christine M. Pierce Campbell, Donna J. Ingles, Krystle A. Lang Kuhs, Alan G. Nyitray, Allan Hildesheim, Michael Pawlita, Aimée R. Kreimer, Anna R. Giuliano

    Published 2016-12-01
    Get full text
    Article
  3. 3
    Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection

    Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection by Gathoni Kamuyu, Filomeno Coelho da Silva, Vanessa Tenet, John Schussler, Anna Godi, Rolando Herrero, Carolina Porras, Lisa Mirabello, John T. Schiller, Mónica S. Sierra, Aimée R. Kreimer, Gary M. Clifford, Simon Beddows

    Published 2024-02-01
    Get full text
    Article
  4. 4
    Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials

    Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence... by Hilary S. Whitworth, Sandra Mounier-Jack, Edward M. Choi, Katherine E. Gallagher, Natasha Howard, Helen Kelly, Gladys Mbwanji, Aimée R Kreimer, Partha Basu, Ruanne Barnabas, Mélanie Drolet, Marc Brisson, Deborah Watson-Jones

    Published 2024-08-01
    Get full text
    Article
  5. 5
    State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop

    State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop by Anne E. Schuind, Helen Rees, John Schiller, Nelly Mugo, Peter Dull, Ruanne Barnabas, Gary M. Clifford, Gui Liu, Shabir A. Madhi, Rebecca B. Morse, Anna-Barbara Moscicki, Joel M. Palefsky, Stanley Plotkin, Mónica S. Sierra, Mark K. Slifka, Alex Vorsters, Aimée R. Kreimer, Arnaud M. Didierlaurent

    Published 2023-10-01
    Get full text
    Article
  6. 6
    HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

    HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial by Sabrina H. Tsang, John T. Schiller, Carolina Porras, Troy J. Kemp, Rolando Herrero, John Schussler, Monica S. Sierra, Bernal Cortes, Allan Hildesheim, Douglas R. Lowy, Ana Cecilia Rodríguez, Byron Romero, Nicolas Çuburu, Jaimie Z. Shing, Ligia A. Pinto, Joshua N. Sampson, Aimée R. Kreimer, on behalf of the Costa Rica HPV Vaccine Trial Group

    Published 2022-03-01
    Get full text
    Article
  7. 7
    Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trial

    Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trial by Jaimie Z. Shing, Carolina Porras, Maísa Pinheiro, Rolando Herrero, Allan Hildesheim, Danping Liu, Mitchell H. Gail, Byron Romero, John T. Schiller, Michael Zúñiga, Sambit Mishra, Laurie Burdette, Kristine Jones, John Schussler, Rebeca Ocampo, Jianwen Fang, Zhiwei Liu, Douglas R. Lowy, Sabrina H. Tsang, Ana Cecilia Rodríguez, Mark Schiffman, Cameron B. Haas, Loretto J. Carvajal, Jalen R. Brown, Aimée R. Kreimer, Lisa Mirabello, Costa Rica HPV Vaccine Trial (CVT) Group

    Published 2024-06-01
    Get full text
    Article
  8. 8
    Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial

    Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised contro... by Kathy Baisley, MSc, Troy J Kemp, PhD, Aimée R Kreimer, PhD, Partha Basu, PhD, John Changalucha, MSc, Allan Hildesheim, PhD, Carolina Porras, MSc, Hilary Whitworth, PhD, Rolando Herrero, PhD, Charles J Lacey, MD, John T Schiller, PhD, Eric Lucas, MSc, Paul Mutani, MD, Joakim Dillner, PhD, Jackton Indangasi, MSc, Richard Muwonge, PhD, Richard J Hayes, DSc, Ligia A Pinto, PhD, Deborah Watson-Jones, PhD

    Published 2022-10-01
    Get full text
    Article

Search Tools: